Global Prostate Cancer Diagnostics Market Size & Trends Report Segmented by Type (Adenocarcinoma, Interstitial Cell Carcinoma), Test Type (Preliminary, Confirmatory), End-user (Hospitals, Outpatient Clinics, Home-care Settings) & Regional Forecast to 2030

1. Introduction
   • Introduction
   • Market Scope
     • Market Definition
     • Segments Covered
     • Regional Segmentation
   • Research Timeframe
   • Currency Considered
   • Study Limitations
   • Stakeholders
   • List of Abbreviations
   • Key Conferences and Events (2025-2026)
2. Research Methodology
   • Secondary Research
   • Primary Research
   • Market Estimation
     • Bottom-Up Approach
     • Top-Down Approach
   • Market Forecasting
3. Executive Summary
   • Prostate Cancer Diagnostics Marke"4">
   • Market Overview
     • Market Dynamics
       • Drivers
         • Rising incidence of prostate cancer globally
         • Advancements in diagnostic technologies
         • Growing awareness and screening programs
         • Increasing geriatric male population
         • Rising R&D investments by med-tech and pharma companies
       • Restraints
         • High cost of diagnostic tests
         • Requirement of high-end labs
         • Stringent regulatory approvals
       • Opportunities
         • Shift towards home-based diagnostic kits
         • Expansion of AI-based diagnostic platforms
         • Rising clinical applications of liquid biopsy in early detection
         • Expansion into emerging markets
       • Key Market Trends
         • Development of genomic tests for risk stratification
         • Rise in demand for multi-parametric MRI
       • Unmet Market Needs
       • Indus"5">
       • Global Prostate Cancer Diagnostics Market Size & Forecast (2023-2030), By Type, USD Million
         • Adenocarcinoma
         • Interstitial Cell Carcinoma
         • Others
       • Global Prostate Cancer Diagnostics Market Size & Forecast (2023-2030), By Test Type, USD Million
         • Preliminary Tests

6.1.1 PSA Tests

6.1.2 Free PSA Test

6.1.3 Total PSA Test

6.1.4 Others

• Confirmatory Tests

6.2.1 Pca3 Test

6.2.2 Trans-Rectal Ultrasound

6.2.3 Biopsy Test"7">

9. Competitive Landscape
   • Key Players and their Competitive Positioning
     • Key Player Comparison
     • Segment-wise Player Mapping
     • Market Share Analysis (2024)
     • Company Categorization Matrix
       • Dominants/Leaders
       • New Entrants
       • Emerging Players
       • Innovative Players
     • Key Strategies Assessment, By Player (2022-2025)
       • New Product Launches
       • Partnerships, Agreements, & Collaborations
       • Mergers & Acquisitions
       • Geographic Expansion

10. Company Profiles*

(Business Overview, Financial Performance**, Products Offered, Recent Developments)

• Hoffmann-La Roche Ltd
• Abbott Laboratories
• MDx Healthcare, Inc.
• Myriad Genetics
• Siemens Healthineers AG
• ACON Laboratories
• Humasis Co, Ltd
• Opko Health
• Beckman Coulter, Inc.
• Diasorinp. A.
• Ipsen Pharma
• Other Prominent Players

Note: *Indicative list

**For listed companies